Zydus Lifesciences' stock declines despite subsidiary inking exclusive licensing deal with Synthon; details here

This follows the announcement that the pharmaceutical’s wholly-owned subsidiary Zydus Lifesciences Global FZE signed an exclusive license and supply agreement with Netherlands-based Synthon BV for Ozanimod Capsule, a generic version of Zeposia, for the US market.

Drugmaker Synthon has a pending abbreviated new drug application in the United States, seeking approval for Ozanimod Capsules, used for relapsing forms of multiple sclerosis, Zydus said in a regulatory filing dated Thursday.

Under the agreement, Synthon will obtain regulatory approval for Ozanimod Capsules, following which, it will also be responsible for manufacturing and supplying the drug.

The filing added that Zydus will be responsible for the commercialisation of the capsules in the United States.

Synthon received tentative approval from the USFDA (US Food and Drug Administration) within 30 months, as the company was one of the first filers. This makes the capsules eligible for a shared 180-day exclusivity upon market entry.

Commenting on the licensing deal, Punit Patel, President and Chief Executive Officer of Zydus Pharmaceuticals, said: “This collaboration with Synthon enables us to bring this important treatment to the U.S. market. This collaboration reinforces our strategic focus on advancing care in therapeutic areas and reflects our commitment to making essential medicines more accessible to patients.”

Zeporsia (Ozanimod) is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults, the statement said.

The drug is also approved for moderately to severely active ulcerative colitis (UC) in adults.

“This collaboration with Zydus for Ozanimod capsules continues to underscore our proven expertise in developing first-to-market, complex generic products. We are pleased to strengthen our partnership with Zydus as we continue advancing our strategic commitment to expanding access to essential medicines,” said Anish Mehta, the Chief Executive Officer of Synthon BV.

Zeprosia is a trademark of Receptos, a Bristol Myers Squibb company, the statement said.

Zydus Lifescience share performance

The stock advanced 2.97% over the week and 6.01% over the month. It gained 5.57% over three months. On a year-to-date basis, however, the scrip plunged 10.15%.

Zydus Lifescience has a total market capitalisation of ₹1.02 lakh crore, as of September 5, 2025, according to data on the NSE.